Literature DB >> 20100637

Management of prostate cancer recurrence after definitive radiation therapy.

Christian Boukaram1, Jean-Michel Hannoun-Levi.   

Abstract

The management of prostate cancer (PC) recurrence after definitive radiation therapy (RT) is shifting and there is no consensus regarding the optimal strategy. The major challenge is determining the anatomical site of relapse. In case of biochemical relapse (BR), androgen deprivation therapy (ADT) is a non-curative option commonly used, while patients with a local PC recurrence could be managed through a curative intent. Based on a Pubmed data search, this manuscript focused on the management of post-RT local PC recurrences. In case of BR (nadir+2 ng/ml), classical imaging work-up is not contributive for PSA levels <10 ng/ml while new imaging investigations (diffusion MRI, 11C-choline PET) are more sensitive to detect local and distant recurrences at lower PSA levels. Positive prostate biopsies are the only method for confirming local recurrence, although this technique presents limitations. Primary PC presentation as well as PSA-related features (interval to failure, PSA kinetic) and patient features (life expectancy, urinary, sexual status) are important to consider. Results of curative salvage options (radical prostatectomy, cryotherapy, brachytherapy and high-intensity focused ultrasound-HIFU) are analyzed and discussed. Each of these therapies appears feasible and has its own set of experience and toxicity profile. Other therapeutic options (photodynamic therapy, ADT, observation) are discussed. Longer follow-up and mature series are needed to evaluate the optimal strategy and prospective trials are warranted. Each clinical situation should be discussed in a multidisciplinary setting. Different options should be explained to the patient and decision should be taken after balancing treatment outcomes with life expectancy. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20100637     DOI: 10.1016/j.ctrv.2009.06.006

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  11 in total

1.  Salvage prostatectomy post-definitive radiation therapy: The Vancouver experience.

Authors:  Niall M Corcoran; Guilherme Godoy; Rodney C Studd; Rowan G Casey; Antonio Hurtado-Coll; Scott Tyldesley; S Larry Goldenberg; Martin E Gleave
Journal:  Can Urol Assoc J       Date:  2013 Mar-Apr       Impact factor: 1.862

2.  Analysis of intraprostatic therapeutic effects in prostate cancer patients using [(11)C]-choline pet/ct after external-beam radiation therapy.

Authors:  J Amanie; H S Jans; M Wuest; N Pervez; A Murtha; N Usmani; D Yee; R Pearcey; B Danielson; S Patel; R Macewan; C Field; D Robinson; J Wilson; D Lewis; M Parliament; A J B McEwan
Journal:  Curr Oncol       Date:  2013-04       Impact factor: 3.677

Review 3.  MR imaging of treated prostate cancer.

Authors:  Hebert Alberto Vargas; Cecilia Wassberg; Oguz Akin; Hedvig Hricak
Journal:  Radiology       Date:  2012-01       Impact factor: 11.105

4.  Androgen deprivation therapy and cardiovascular risk.

Authors:  Sanoj Punnen; Matthew R Cooperberg; Natalia Sadetsky; Peter R Carroll
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

5.  Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy?

Authors:  Olivio F Donati; Sung Il Jung; Hebert Alberto Vargas; David H Gultekin; Junting Zheng; Chaya S Moskowitz; Hedvig Hricak; Michael J Zelefsky; Oguz Akin
Journal:  Radiology       Date:  2013-03-12       Impact factor: 11.105

6.  Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.

Authors:  Oluwaseun A Odewole; Funmilayo I Tade; Peter T Nieh; Bital Savir-Baruch; Ashesh B Jani; Viraj A Master; Peter J Rossi; Raghuveer K Halkar; Adeboye O Osunkoya; Oladunni Akin-Akintayo; Chao Zhang; Zhengjia Chen; Mark M Goodman; David M Schuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-18       Impact factor: 9.236

Review 7.  Role of focal salvage ablative therapy in localised radiorecurrent prostate cancer.

Authors:  A Kanthabalan; M Arya; S Punwani; A Freeman; A Haroon; J Bomanji; M Emberton; H U Ahmed
Journal:  World J Urol       Date:  2013-12       Impact factor: 4.226

Review 8.  Kallikreins as biomarkers for prostate cancer.

Authors:  Sung Kyu Hong
Journal:  Biomed Res Int       Date:  2014-04-07       Impact factor: 3.411

Review 9.  Focal low-dose rate brachytherapy for the treatment of prostate cancer.

Authors:  William Y Tong; Gilad Cohen; Yoshiya Yamada
Journal:  Cancer Manag Res       Date:  2013-09-13       Impact factor: 3.989

10.  Mechanisms of growth inhibition of primary prostate epithelial cells following gamma irradiation or photodynamic therapy include senescence, necrosis, and autophagy, but not apoptosis.

Authors:  Fiona M Frame; Huguette Savoie; Francesca Bryden; Francesca Giuntini; Vincent M Mann; Matthew S Simms; Ross W Boyle; Norman J Maitland
Journal:  Cancer Med       Date:  2015-11-21       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.